KR102817790B1 - C-c 케모카인 수용체 4(ccr4) 길항제 및 하나 이상의 면역 체크포인트 억제제를 사용한 병용 요법 - Google Patents

C-c 케모카인 수용체 4(ccr4) 길항제 및 하나 이상의 면역 체크포인트 억제제를 사용한 병용 요법 Download PDF

Info

Publication number
KR102817790B1
KR102817790B1 KR1020217008833A KR20217008833A KR102817790B1 KR 102817790 B1 KR102817790 B1 KR 102817790B1 KR 1020217008833 A KR1020217008833 A KR 1020217008833A KR 20217008833 A KR20217008833 A KR 20217008833A KR 102817790 B1 KR102817790 B1 KR 102817790B1
Authority
KR
South Korea
Prior art keywords
alkyl
compound
cancer
group
ccr4
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
KR1020217008833A
Other languages
English (en)
Korean (ko)
Other versions
KR20210053306A (ko
Inventor
시지에 리
벤캇 레디 말리
라진더 싱
주 양
펭라이 장
Original Assignee
케모센트릭스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 케모센트릭스, 인크. filed Critical 케모센트릭스, 인크.
Publication of KR20210053306A publication Critical patent/KR20210053306A/ko
Application granted granted Critical
Publication of KR102817790B1 publication Critical patent/KR102817790B1/ko
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/357—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having two or more oxygen atoms in the same ring, e.g. crown ethers, guanadrel
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/445—Non condensed piperidines, e.g. piperocaine
    • A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
    • A61K31/4545—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a six-membered ring with nitrogen as a ring hetero atom, e.g. pipamperone, anabasine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
    • A61K39/39541—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against normal tissues, cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C07K16/2818—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/82—Colon
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/80—Vaccine for a specifically defined cancer
    • A61K2039/852—Pancreas
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Mycology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Microbiology (AREA)
  • Biomedical Technology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
KR1020217008833A 2018-08-29 2019-08-28 C-c 케모카인 수용체 4(ccr4) 길항제 및 하나 이상의 면역 체크포인트 억제제를 사용한 병용 요법 Active KR102817790B1 (ko)

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201862724412P 2018-08-29 2018-08-29
US62/724,412 2018-08-29
US201862771853P 2018-11-27 2018-11-27
US62/771,853 2018-11-27
PCT/US2019/048461 WO2020047030A1 (en) 2018-08-29 2019-08-28 Combination therapy using c-c chemokine receptor 4 (ccr4) antagonists and one or more immune checkpoint inhibitors

Publications (2)

Publication Number Publication Date
KR20210053306A KR20210053306A (ko) 2021-05-11
KR102817790B1 true KR102817790B1 (ko) 2025-06-05

Family

ID=69639506

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1020217008833A Active KR102817790B1 (ko) 2018-08-29 2019-08-28 C-c 케모카인 수용체 4(ccr4) 길항제 및 하나 이상의 면역 체크포인트 억제제를 사용한 병용 요법

Country Status (16)

Country Link
US (2) US11446289B2 (enExample)
EP (1) EP3843734B1 (enExample)
JP (1) JP7554180B2 (enExample)
KR (1) KR102817790B1 (enExample)
CN (1) CN112601526B (enExample)
AU (1) AU2019327430B2 (enExample)
BR (1) BR112021002928A2 (enExample)
CA (1) CA3109498A1 (enExample)
ES (1) ES3064498T3 (enExample)
IL (1) IL280831B2 (enExample)
MA (1) MA53503A (enExample)
MX (1) MX2021002302A (enExample)
SG (1) SG11202101454PA (enExample)
TW (1) TWI888358B (enExample)
WO (1) WO2020047030A1 (enExample)
ZA (1) ZA202101055B (enExample)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6141864B2 (ja) 2011-12-01 2017-06-07 ケモセントリックス，インコーポレイティド Ｃｃｒ（４）アンタゴニストとしての置換アニリン
ES3064498T3 (enExample) * 2018-08-29 2026-04-27 Chemocentryx Inc
KR20230149729A (ko) * 2022-04-19 2023-10-27 케모센트릭스, 인크. Ccr4 길항제

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073759A1 (en) * 2014-11-05 2016-05-12 The Regents Of The University Of California Combination immunotherapy
WO2018101448A1 (en) * 2016-11-30 2018-06-07 Kyowa Hakko Kirin Co., Ltd. Method of treating cancer using anti-ccr4 antibody and anti-pd-1 antibody

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5476996A (en) 1988-06-14 1995-12-19 Lidak Pharmaceuticals Human immune system in non-human animal
US20020173524A1 (en) * 2000-10-11 2002-11-21 Tularik Inc. Modulation of CCR4 function
AU2003256923A1 (en) 2002-07-31 2004-02-16 Smithkline Beecham Corporation Substituted benzanilides as modulators of the ccr5 receptor
JP2007210887A (ja) 2004-06-21 2007-08-23 Astellas Pharma Inc 縮合二環性ピリミジン誘導体
US20090182140A1 (en) 2005-12-02 2009-07-16 Mitsubishi Tanabe Pharma Corporation Alicyclic Heterocyclic Compound
GB0718167D0 (en) 2007-09-18 2007-10-31 Cancer Rec Tech Ltd Cancer marker and therapeutic target
JP2009148309A (ja) 2007-12-18 2009-07-09 Uni Charm Corp 吸収性物品
US8263073B2 (en) 2008-02-04 2012-09-11 Medarex, Inc. Anti-CTLA-4 antibodies with reduced blocking of binding of CTLA-4 to B7 and uses thereof
JP5523572B2 (ja) 2009-10-26 2014-06-18 中国石油化工股▲ふん▼有限公司 担持型非メタロセン触媒、その製造方法およびその使用
WO2011050565A1 (zh) 2009-10-26 2011-05-05 中国石油化工股份有限公司 负载型非茂金属催化剂、其制备方法及其应用
WO2011056423A2 (en) 2009-10-28 2011-05-12 Exxonmobil Chemical Patents Inc. Catalyst compounds and use thereof
US8952113B2 (en) 2009-11-13 2015-02-10 China Petroleum & Chemical Corp. Supported nonmetallocene catalyst, preparation and use thereof
EP2500364B1 (en) 2009-11-13 2020-03-04 China Petroleum & Chemical Corporation Supported non-metallocene catalyst preparation method and application thereof
US20140031547A1 (en) 2010-12-14 2014-01-30 Electrophoretics Limited CASEIN KINASE 1delta (CK 1delta) INHIBITORS AND THEIR USE IN THE TREATMENT OF NEURODE-GENERATIVE DISEASES SUCH AS TAUOPATHIES
JP6141864B2 (ja) * 2011-12-01 2017-06-07 ケモセントリックス，インコーポレイティド Ｃｃｒ（４）アンタゴニストとしての置換アニリン
CA2899577C (en) * 2013-04-03 2023-10-17 Ibc Pharmaceuticals, Inc. Combination therapy for inducing immune response to disease
WO2016181349A1 (en) * 2015-05-14 2016-11-17 Pfizer Inc. Combinations comprising a pyrrolidine-2,5-dione ido1 inhibitor and an anti-body
TW201713332A (zh) * 2015-07-14 2017-04-16 協和醱酵麒麟有限公司 包含與抗體組合投予之ｉｄｏ抑制物之腫瘤治療劑
TWI724056B (zh) * 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
SG10201603721TA (en) 2016-05-10 2017-12-28 Agency Science Tech & Res Anti-CTLA-4 Antibodies
KR102401963B1 (ko) 2016-06-27 2022-05-25 케모센트릭스, 인크. 면역조절제 화합물
PL3490565T3 (pl) * 2016-07-29 2022-09-26 Rapt Therapeutics, Inc. Pochodne azetydyny jako modulatory receptora chemokinowego i ich zastosowanie
WO2018035710A1 (en) 2016-08-23 2018-03-01 Akeso Biopharma, Inc. Anti-ctla4 antibodies
ES3064498T3 (enExample) * 2018-08-29 2026-04-27 Chemocentryx Inc

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016073759A1 (en) * 2014-11-05 2016-05-12 The Regents Of The University Of California Combination immunotherapy
WO2018101448A1 (en) * 2016-11-30 2018-06-07 Kyowa Hakko Kirin Co., Ltd. Method of treating cancer using anti-ccr4 antibody and anti-pd-1 antibody

Also Published As

Publication number Publication date
CA3109498A1 (en) 2020-03-05
ZA202101055B (en) 2025-08-27
NZ773164A (en) 2025-07-25
US12011439B2 (en) 2024-06-18
WO2020047030A1 (en) 2020-03-05
KR20210053306A (ko) 2021-05-11
EP3843734B1 (en) 2026-01-28
TWI888358B (zh) 2025-07-01
US20230097128A1 (en) 2023-03-30
TW202023555A (zh) 2020-07-01
MX2021002302A (es) 2021-04-28
IL280831B2 (en) 2024-05-01
JP2021536442A (ja) 2021-12-27
US11446289B2 (en) 2022-09-20
SG11202101454PA (en) 2021-03-30
MA53503A (fr) 2021-07-07
JP7554180B2 (ja) 2024-09-19
AU2019327430A1 (en) 2021-03-18
AU2019327430B2 (en) 2024-10-03
EP3843734C0 (en) 2026-01-28
EP3843734A1 (en) 2021-07-07
BR112021002928A2 (pt) 2021-05-11
IL280831B1 (en) 2024-01-01
CN112601526B (zh) 2025-10-03
EP3843734A4 (en) 2022-05-25
CN112601526A (zh) 2021-04-02
US20200069673A1 (en) 2020-03-05
ES3064498T3 (enExample) 2026-04-27
IL280831A (en) 2021-04-29

Similar Documents

Publication Publication Date Title
JP7337833B2 (ja) 縮合二環式Ｃ５ａＲアンタゴニストのプロドラッグ
ES2816060T3 (es) Aza-aril 1H-pirazol-1-il-bencenosulfonamidas como antagonistas de CCR(9)
US12011439B2 (en) Combination therapy using C—C chemokine receptor 4 (CCR4) antagonists and one or more immune checkpoint inhibitors
KR102736360B1 (ko) C5aR 억제제로서의 디아릴 치환된 6,5-융합 고리 화합물
CA3139526A1 (en) Triaryl compounds for treatment of pd-l1 diseases
EP3474845A1 (en) Immunomodulator compounds
JP2023181168A (ja) ケモカイン受容体２（ｃｃｒ２）アンタゴニスト及びｐｄ－１／ｐｄ－ｌ１阻害剤を使用した併用療法
AU2004251754A1 (en) Methods and compositions for treating rheumatoid arthritis
US20240115682A1 (en) Methods of treating cancer using heteroaryl-biphenyl amide derivatives
TW201736345A (zh) 2-羥吲哚化合物
TW201938160A (zh) 以ccr2拮抗劑治療實體腫瘤的方法
AU2023255619A1 (en) Ccr4 antagonists
TWI664174B (zh) 雜環化合物及其用途
RU2810717C2 (ru) Комбинированная терапия с использованием антагонистов c-c хемокинового рецептора 4 (ccr4) и одного или более ингибиторов контрольных точек
WO2018187509A1 (en) Heterocyclic compounds as chemokine receptor modulators
KR20230025869A (ko) Tlr7/8 길항제 및 이의 용도
EA048430B1 (ru) Способы комбинированной терапии
HK40000508B (en) 2-oxindole compounds
HK40000508A (en) 2-oxindole compounds

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 20210324

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 20220822

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20250120

Patent event code: PE09021S01D

E701 Decision to grant or registration of patent right
PE0701 Decision of registration

Patent event code: PE07011S01D

Comment text: Decision to Grant Registration

Patent event date: 20250523

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20250602

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20250602

End annual number: 3

Start annual number: 1

PG1601 Publication of registration